{"id":"axs-07","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Chest discomfort"},{"rate":null,"effect":"Paresthesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines melitracen, which modulates monoamine reuptake and has analgesic properties, with rizatriptan, a selective 5-HT1B/1D receptor agonist (triptan). This combination is designed to provide faster onset and potentially greater efficacy than rizatriptan alone for acute migraine treatment. The melitracen component may enhance the triptan's effect through complementary mechanisms.","oneSentence":"AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:14.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute migraine with or without aura"}]},"trialDetails":[{"nctId":"NCT04163185","phase":"PHASE3","title":"Initiating Early Control of Migraine Pain and Associated Symptoms","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-10-08","conditions":"Migraine","enrollment":302},{"nctId":"NCT05550207","phase":"PHASE3","title":"Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2022-08-31","conditions":"Migraine","enrollment":100},{"nctId":"NCT04068051","phase":"PHASE3","title":"Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-07-06","conditions":"Migraine","enrollment":706},{"nctId":"NCT03896009","phase":"PHASE3","title":"Maximizing Outcomes in Treating Acute Migraine","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-03-04","conditions":"Migraine","enrollment":1594}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AXS-07","genericName":"AXS-07","companyName":"Axsome Therapeutics, Inc.","companyId":"axsome-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief. Used for Acute migraine with or without aura.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}